Texas
LATEST FROM BIOSPACE
AlloVir is working to develop an allogeneic cell therapy to control infections in immunocompromised patients, typically after they undergo organ transplants.
Merck is buying all outstanding shares of Peloton, a clinical-stage oncology company, for an upfront payment of $1.05 billion in cash. Peloton will also be eligible for another $1.15 billion based on various regulatory and sales milestones.
Some of the biggest hubs for biotech and pharma fared poorly in the rankings due to housing affordability.
The company took its GSK-3B inhibitor into the clinic earlier this year. The drug is being studied in patients with refractory hematologic malignancies or solid tumors.
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
As a valued member of our BioSpace community, we are eager to hear more from you and other readers in 2019. We want to know your ‘right opportunity’ to consider a new job.
Curbing the opioid crisis will continue to be a key focus for the FDA. Ned Sharpless talked about new packaging rules that are expected to help stem the concerns about too many opioids on the streets.
According to a recent BioSpace survey, 93% of respondents are open to a new job for the right opportunity. Are you one of the 93%? If so, keep your eyes open for those opportunities and don’t stop looking. You never know what may come your way!
Four biotech companies recently filed with the U.S. Securities and Exchange Commission their plans for initial public offerings (IPO). Let’s take a look.
A new poll shows nearly two-thirds of people blame the pharmaceutical companies for the opioid crisis.
PRESS RELEASES